0.20Open0.20Pre Close0 Volume1 Open Interest26.00Strike Price0.00Turnover162.25%IV28.67%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.0541Delta0.0137Gamma180.85Leverage Ratio-0.0613Theta-0.0004Rho-9.79Eff Leverage0.0054Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet